The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools).
NONMEM
allopurinol
dose
gout
pharmacokinetic-pharmacodynamic
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
revised:
08
01
2024
received:
29
11
2023
accepted:
10
01
2024
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
15
2
2024
Statut:
aheadofprint
Résumé
Dose escalation at the initiation of allopurinol therapy can be protracted and resource intensive. Tools to predict the allopurinol doses required to achieve target serum urate concentrations would facilitate the implementation of more efficient dose-escalation strategies. The aim of this research was to develop and externally evaluate allopurinol dosing tools, one for use when the pre-urate-lowering therapy serum urate is known (Easy-Allo1) and one for when it is not known (Easy-Allo2). A revised population pharmacokinetic-pharmacodynamic model was developed using data from 653 people with gout. Maintenance doses to achieve the serum urate target of <0.36 mmol L Allopurinol doses were predicted by total body weight, baseline urate, ethnicity and creatinine clearance. Easy-Allo1 produced unbiased and suitably precise dose predictions (MPE 2 mg day The Easy-Allo tools provide a guide to the allopurinol maintenance dose requirement to achieve the serum urate target of <0.36 mmol L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Arthritis New Zealand
Organisme : Canterbury Medical Research Foundation
Organisme : New Zealand Pharmacy Education and Research Foundation
Organisme : Health Research Council of New Zealand
Organisme : Ardea Biosciences, Inc.
Informations de copyright
© 2024 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744-760. doi:10.1002/acr.24180
Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529-2536. doi:10.1002/art.34488
Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522-1528. doi:10.1136/annrheumdis-2016-210872
Stamp LK, Chapman PT, Barclay ML, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann Rheum Dis. 2017;76(12):2065-2070. doi:10.1136/annrheumdis-2017-211873
Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392(10156):1403-1412. doi:10.1016/S0140-6736(18)32158-5
Phang KF, Santosa A, Low BP, et al. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout. Int J Rheum Dis. 2020;23(9):1136-1144. doi:10.1111/1756-185X.13855
Cheong KM, Sriranganathan MK, Lee EM. Impact of pharmacist-led collaborative gout clinic on timely achievement of serum uric acid goals. Proc Singapore Healthcare. 2023;32:1-12. doi:10.1177/20101058231152048
Mikuls TR, Cheetham TC, Levy GD, et al. Adherence and outcomes with urate-lowering therapy: a site-randomized trial. Am J Med. 2019;132(3):354-361. doi:10.1016/j.amjmed.2018.11.011
Wright DFB, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81(2):277-289. doi:10.1111/bcp.12799
Wright D, Dalbeth N, Phipps-Green A, et al. The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. Br J Clin Pharmacol. 2018;84(5):937-943. doi:10.1111/bcp.13516
Kannangara DR, Graham GG, Wright DF, et al. Individualising the dose of allopurinol in patients with gout. Br J Clin Pharmacol. 2017;83(9):2015-2026. doi:10.1111/bcp.13307
Graham GG, Kannangara DR, Stocker SL, et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol. 2013;76(6):932-938. doi:10.1111/bcp.12126
Stamp LK, Barclay ML, O'Donnell JL, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther. 2011;90(3):392-398. doi:10.1038/clpt.2011.113
Stamp LK, Barclay M, O'Donnell JL, et al. Furosemide increases plasma oxypurinol without lowering serum urate-a complex drug interaction: implications for clinical practice. Rheumatology. 2012;51(9):1670-1676. doi:10.1093/rheumatology/kes091
Stamp LK, O'Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. Arthritis Rheum. 2013;65(6):1636-1642. doi:10.1002/art.37925
Becker M, Fitz-Patrick D, Choi H, et al. An open label, 6-month study of allopurinol safety in gout: the LASSO study. Semin Arthritis Rheum. 2015;2015(45):174-183. doi:10.1016/j.semarthrit.2015.05.005
Smith-Diaz N, Stocker SL, Stamp LK, et al. An allopurinol adherence tool using plasma oxypurinol concentrations. Br J Clin Pharmacol. 2023;89(7):1956-1964. doi:10.1111/bcp.15516
Anon Uric acid assay package insert for the ARCHITECT system. Abbott Laboratories; 2012.
Phipps-Green AJ, Merriman ME, Topless R, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2016;75(1):124-130. doi:10.1136/annrheumdis-2014-205877
Stocker SL, McLachlan AJ, Savic RM, et al. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol. 2012;74(3):477-489. doi:10.1111/j.1365-2125.2012.04207.x
Hishe HZ, Stocker SL, Stamp LK, et al. The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics. Clin Transl Sci. 2023;16(3):422-428. doi:10.1111/cts.13460
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. doi:10.1159/000180580
Phipps-Green AJ, Hollis-Moffatt JE, Dalbeth N, et al. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets. Hum Mol Genet. 2010;19(24):4813-4819. doi:10.1093/hmg/ddq412
Dansirikul C, Silber HE, Karlsson MO. Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn. 2008;35(3):269-283. doi:10.1007/s10928-008-9088-2
Stamp L, Horne A, Mihov B, et al. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Ann Rheum Dis. 2023;82(12):ard-2023-224731. doi:10.1136/ard-2023-224731
Alexander SP, Fabbro D, Kelly E, et al. The concise guide to PHARMACOLOGY 2023/24: transporters. Br J Pharmacol. 2023 Oct;180(S2):S374-S469. doi:10.1111/bph.16182
Knake C, Stamp LK, Bahn A. Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment. Biochem Biophys Res Commun. 2014;452(1):157-162. doi:10.1016/j.bbrc.2014.08.068
Wen CC, Yee SW, Liang X, et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015;97(5):518-525. doi:10.1002/cpt.89
Stamp LK, Wallace M, Roberts RL, et al. ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol. Drug Metab Pharmacokinet. 2018;33(6):241-242. doi:10.1016/j.dmpk.2018.09.002
Brackman DJ, Yee SW, Enogieru OJ, et al. Genome-wide association and functional studies reveal novel pharmacological mechanisms for allopurinol. Clin Pharmacol Ther. 2019;106(3):623-631. doi:10.1002/cpt.1439
Vora B, Brackman DJ, Zou L, et al. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: influence of BCRP Q141K polymorphism and patient characteristics. Clin Transl Sci. 2021;14(4):1431-1443.
Roberts RL, Wallace MC, Phipps-Green AJ, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2017;17(2):201-203. doi:10.1038/tpj.2015.101
Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology. 2017;56(5):679-688. doi:10.1093/rheumatology/kew293
Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412-421. doi:10.1002/art.30119
Ranieri L, Contero C, Peral ML, Calabuig I, Zapater P, Andres M. Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. Arthritis Res Ther. 2018;20(1):1-6. doi:10.1186/s13075-018-1559-2
Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Care Res. 2002;47(6):610-613. doi:10.1002/art.10792